👉INBS is TODAY’S #1 ALERT 👈

Hey Folks, Jeff Bishop here,

Stock futures were up again this morning, raising the prospect of another green day ahead of the Fed’s Wednesday rate decision.

I’m on a roll with my “tactical trade” ideas. I nailed six double-digit winners last week (including 33% and 46% movers), and yesterday’s idea peaked at 8%.

💥My target right now is Intelligent Bio Solutions Inc. (INBS). 

If you check out its chart, you’ll see that over the summer, it based multiple times from the $1.40–$1.50 range…

That zone looks like a reliable support floor, from which it made two big moves into the $2.00+ range. 

After a dip in August, the stock has been stair-stepping higher, from ~$1.40 to $1.55 and now $1.70+ — a 20% rise since August 20.

If INBS keeps holding $1.50 support and pushes through $2.00, the next upside target could be ~$2.40. 

Above that, a run toward $2.50 isn’t crazy given past volatility.

💥Dial into INBS today to see where this momentum takes it.

👉 INBS is TODAY’S #1 ALERT 👈

Intelligent Bio Solutions is “a medical technology company delivering intelligent, rapid, non-invasive testing solutions.” 

Its Intelligent Fingerprinting Drug Testing Solution is “revolutionizing portable testing through fingerprint sweat analysis.”

The New York City-based company has more than 450 accounts across 24 countries, including in Australia, the UK, Scandinavia, and Europe broadly, and has “active scoping underway in Canada, Indonesia, and the Philippines.”

INBS’ Intelligent Fingerprinting Drug Screening System

The Holy Grail, of course, is the U.S. market, and the company is diligently pursuing FDA 510(k) clearance.

Here are the top 5 things to know about INBS:

1. The non-invasive, sweat-fingerprint tech vs old school methods

INBS has built its drug screening system around fingerprint sweat samples rather than urine, blood, or saliva. 

That makes tests way faster, more hygienic, and less invasive. 

You can test just about anywhere — don’t need a private room — and you don’t have the same disposal or biohazard issues.

For safety-critical industries (think transportation, construction, and waste management), that kind of speed + dignity + safety reduces friction for compliance.

2. Strong IP protection + recent patent wins

The company has been stacking up patents. On March 26, INBS was granted its 6th U.S. patent for its fingerprint screening cartridge, giving it a legal moat to protect its tech.

That’s crucial because the market for drug screening/detection is crowded and regulated, so being undercut by knock‐offs is less likely with good patents.

3. FDA 510(k) clearance is within reach — a big inflection point

INBS submitted its 510(k) package (the U.S. premarket approval pathway for medical devices) in December 2024.

It strengthened the submission in July with data confirming its device’s “ability to detect and analyze trace levels of sweat in a single fingerprint” and in August with “intensive cybersecurity testing.”

It said it dedicated more than 10,000 hours to collecting new data for the submission and is aiming for “U.S. market entry in 2025.”

4. Growing recurring revenue from cartridges and deployments

Notably, cartridge sales (the consumable part of its system) are growing. These “higher-margin consumable[s] … form the foundation of INBS’s razor/razor blade business model.”

The company reported more than 12,500 cartridge sales in July 2025, a 60% increase year over year.

And on August 15, it announced fiscal 2025 fourth quarter and full year results, including:

• Revenue of $843,884 — up 16% from the prior quarter
• Cartridge sales increased 24% year-on-year for the fiscal fourth quarter
• The company secured 115 new accounts throughout the year

5. Capital strategy

On July 25, the company revealed it had raised gross proceeds of $3.8 million through warrant exercises, which it intended to use “to fund completion of its 510k filing with the U.S. FDA for its Fingerprint Drug Screening System, for working capital and general corporate purposes.”

That almost certainly spurred its stock’s late-July/mid-August dip from which it’s currently recovering.

Final Thoughts

As you do your own research on INBS, be sure to check out the company’s slick and accessible website and its August 2025 investor presentation.

And of course, always approach your trading in a responsible manner,  remembering that trading is very risky. Nothing is ever guaranteed, so never trade with more than you can afford to lose. 

Please read the full disclaimer at the bottom of this email as well, so you are aware of additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

To Your Success,

Jeff Bishop

P.S. Make sure you join me and over 1000 traders in the Market Master’s trading room today for live trading signals and education. You can access it at no cost right now. 

*DISCLAIMER: This entity is owned by Sherwood Ventures LLC (SV). To more fully understand any SV subscription, website, application or other service, please review our full disclaimer located at https://bullseyealerts.com/disclaimer/

Just so you know, what you’re reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let’s be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren’t what you’d call “typical.”

Just a quick heads up about this ad you’re reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received fifteen thousand dollars (cash) from Virtus Media Group for advertising Intelligent Bio Solutions, Inc for a one day marketing program starting on September 16, 2025. It might seem obvious, but while our client claims not to own any shares in Intelligent Bio Solutions, Inc, whoever ultimately paid them most likely owns shares. You should assume they are looking to sell some or all of them at any time after we send out this information, which might negatively affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither Sherwood Ventures nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as the marketing campaign ends, though that is not always the case.

Now, diving right into Intelligent Bio Solutions, Inc might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there’s exceptional risk involved in trading. This isn’t small potatoes we’re talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We’re shining a light on the good stuff about the company here, but it’s on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we’re not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies who are paying us and we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can’t wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who’s licensed to give you real advice. To be clear, neither Sherwood Ventures nor its owners, employees, or independent contractors are registered as a securities broker-dealer, broker, 1nvest.ment advis0r (IA), or IA rep’s with the SEC, any state securities regulatory authority, or any self-regu1atory organization.

So, that’s the scoop! If you’re intrigued and want to learn more about the companies we talk about, hit up the SEC’s website to dig into their filings and see the full picture.